Results 21 to 30 of about 21,604,258 (289)
Chimeric Antigen Receptor T-Cell Therapy
Various cytotoxic approaches for cancer therapy have been developed over the years. However, due to their limited efficacy, there is a continual search for therapeutic approaches with better outcomes, such as immunotherapy that develops and augments the patient's immune system.
Sunil B Rajadhyaksha +2 more
+11 more sources
Breast cancer represents one of the most common tumor histologies. To date, based on the specific histotype, different therapeutic strategies, including immunotherapies, capable of prolonging survival are used. More recently, the astonishing results that
Caterina Gianni +8 more
core +2 more sources
Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
Glioblastoma (GBM), the most common primary brain tumor in adults, is characterized by low survival rates and a grim prognosis. Current treatment modalities, including extensive surgical resection, chemotherapy, and radiation therapy, often yield limited success due to the brain’s sensitivity, leading to significant side effects.
Ma, Kun, Hu, Ping
openaire +2 more sources
Dataset of the study “Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia”
Jiakui Zhang (8521494) +16 more
core +2 more sources
Chimeric antigen receptor T-cell therapy for ALL [PDF]
Abstract Relapsed and refractory leukemias pose substantial challenges in both children and adults, with very little progress being made in more than a decade. Targeted immunotherapy using chimeric antigen receptor (CAR)-modified T cells has emerged as a potent therapy with an innovative mechanism.
Shannon L, Maude +2 more
openaire +2 more sources
Chimeric Antigen Receptor T-Cell Therapy for Lymphomas [PDF]
It is estimated that 2.1% of the population of the United States will develop non-Hodgkin lymphoma (NHL) in a lifetime. With treatment, 71% of patients with NHL live to 5 years. Because current drugs used for treatment do not cure all patients and cause serious adverse effects, new strategies have been studied to treat lymphoma.
Benjamin, Jolley, Scot, Walker
openaire +2 more sources
Outcomes for post-chimeric antigen receptor (CAR) T cell therapy (CART) relapse are poor. The utilization of a unique CAR T cell construct for post-CART failure is increasing, but this approach is not well described. In this study, with CART-A the first unique CAR T cell construct received and CART-B the second, the primary objective was to ...
Elizabeth M. Holland +15 more
openaire +2 more sources
Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor +8 more
core +1 more source
Chimeric Antigen Receptor T-cell Therapy (CAR T)
This is an adoptive T-cell therapy which uses engineered T-cell. In which they are obtain from a patient’s immune system by its own to attack cancer cells through targeting proteins expressed on the cellular membrane, that process involves obtaining T ...
Dr. Vachaspati Narayan, Dr. Mahender Miland, Dr. Kritika Gahlot, Dr. Mukul Purva
core +1 more source
Chimeric Antigen Receptor T Cell Therapy: A Review [PDF]
Chimeric Antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). CARs are engineered and constructed specifically to reprogram a
Knouse, Michael
core +1 more source

